AF
TSHA icon

Amalgamated Financial’s Taysha Gene Therapies TSHA Stock Holding History

Amalgamated Financial’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$23K Buy
+3,535
New +$26.4K ﹤0.01% 2704

Other funds holding TSHA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

Amalgamated Financial's TSHA Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Taysha Gene Therapies (TSHA) in Q1 2022: 3,535 shares worth $23K. The stake represents ﹤0.01% of the portfolio and ranks #2704 among its holdings.

71 funds tracked by Wall St. Rank hold TSHA as of Q1 2022.

  • Amalgamated Financial held 3,535 shares of Taysha Gene Therapies worth $23K as of Q1 2022.
  • Taysha Gene Therapies was a new Amalgamated Financial position in Q1 2022.
  • Taysha Gene Therapies made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2704 holding.
  • 71 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.